HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

RPL38 knockdown inhibits the inflammation and apoptosis in chondrocytes through regulating METTL3-mediated SOCS2 m6A modification in osteoarthritis.

AbstractBACKGROUND:
Ribosomal protein L38 (RPL38) was found upregulated in osteoarthritic peripheral blood mononuclear cells, however, its role in progression of osteoarthritis has not been characterized.
METHODS:
The protein levels of RPL38 and SOCS2 in cartilage tissues from OA patients and controls were detected with Western blotting. IL-1β was used to stimulate primary chondrocytes to establish an OA cell model, and RPL38 siRNA (si-RPL38) was transfected into chondrocytes to investigate the effect of RPL38 knockdown on cell viability, apoptosis, inflammatory factor secretion and extracellular matrix degradation. Then, the mechanism that RPL38 regulate the SOCS2 expression and SOCS2-induced chondrocyte dysfunction was explored. The methyltransferase-like 3 (METTL3)-mediated m6A modification of SOCS2 mRNA was confirmed, and the interaction of RPL38 and METTL3 was verified. Moreover, the effects of SOCS2 overexpression on IL-1β-induced chondrocyte dysfunction and SOCS2 knockdown on the restoration of chondrocyte function by siRPL38 were investigated. Finally, RPL38 was knocked down in vivo and its role in OA progression was validated.
RESULTS:
RPL38 was upregulated and SOCS2 was downregulated in OA cartilages. RPL38 knockdown or SOCS2 overexpression either attenuated IL-1β-induced chondrocyte apoptosis, inflammatory cytokine secretion, and ECM degradation. RPL38 directly interacted with METTL3 and it inhibited SOCS2 expression through METTL3-mediated m6A modification. SOCS2 knockdown activated the JAK2/STAT3 proinflammatory pathway and reversed the effects of RPL38 knockdown on IL-1β-induced chondrocyte apoptosis, inflammation and ECM degradation. RPL38 knockdown alleviated cartilage tissue damage and ECM degradation in OA mice.
CONCLUSION:
RPL38 knockdown inhibited osteoarthritic chondrocyte dysfunction and alleviated OA progression through promoting METTL3-m6A-mediated SOCS2 expression.
AuthorsLiang Shi, Hongbo Hu, Pengxiao Sun, Zheng Li, Le Ji, Shizhang Liu, Jianxin Zhang
JournalInflammation research : official journal of the European Histamine Research Society ... [et al.] (Inflamm Res) Vol. 71 Issue 7-8 Pg. 977-989 (Aug 2022) ISSN: 1420-908X [Electronic] Switzerland
PMID35596790 (Publication Type: Journal Article)
Copyright© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Chemical References
  • Interleukin-1beta
  • MicroRNAs
  • RPL38 protein, mouse
  • Ribosomal Proteins
  • Socs2 protein, mouse
  • Suppressor of Cytokine Signaling Proteins
  • Methyltransferases
  • Mettl3 protein, mouse
Topics
  • Animals
  • Apoptosis
  • Chondrocytes
  • Inflammation (metabolism)
  • Interleukin-1beta (metabolism, pharmacology)
  • Leukocytes, Mononuclear (metabolism)
  • Methyltransferases (genetics, metabolism, pharmacology)
  • Mice
  • MicroRNAs (genetics)
  • Osteoarthritis (genetics, metabolism)
  • Ribosomal Proteins (metabolism)
  • Suppressor of Cytokine Signaling Proteins (genetics, metabolism, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: